1Shamseddine AI, Khalifeh MJ, Mourad FH, Chehal AA, Al-Kutoubi A, et al. (2005) Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet 44: 957-967.
2Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, et al. (2008) Correlation between cytidine deaminase genotype and gemcitabine deaminationin blood samples. Nucleosides Nucleotides NucleicAcids 27: 720-725.
3Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, et al. (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12: 1794-1803.
4Honig A, Rieger L, Sutterlin A, Kapp M, Dietl J, et al. (2005) Brain metastases in breast cancer--an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res 25: 1531-1537.
5Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, et al. (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 10: 407-417.
6Ceresa C, Cavaletti G (2011) Drug transporters in chemotherapy induced peripheral neurotoxicity: current knowledge and clinical implications. Curr Med Chem 18: 329-341.
7Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, et al. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther 125: 196-218.
8Stavridi F, Palmieri C (2008) Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev Anticancer Ther 8: 1859-1869.
9Wachters FM, Van Der Graaf WT, Groen HJ (2004) Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. Anti cancer Res 24: 2079-2083.
10Iarussi D, Indolfi P, Galderisi M, BossoneE (2000) Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25: 676-688.
11Scully RE, Lipshultz SE (2007) Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7: 122-128.
12Vantelon JM, Munck JN, Bourhis JH, Pico JL, Fadel C, et al. (2001) Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. Bone Marrow Transplant 27: 531-536.
13Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, et al. (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26: 3709-3714.
14Chang DZ, Olencki T, Budd GT, Peereboom D, Ganapathi R, et al. (2001) Phase I trial ofcapecitabine in combination withinterferon alpha in patientswithmetastatic renal cancer: toxicity and pharmacokinetics. Cancer Chemother Pharmacol 48: 493-498.
15Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, et al. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70.
16Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280-9290.
17Gong C, Yao Y, Wang Y, Liu B, Wu W, et al. (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286: 19127-19137.
18Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, et al. (2011) Cyclin E amplification/over expression is a mechanism of trastuzumab resistance inHER2+ breast cancer patients. Proc Natl Acad Sci 108: 3761-3766.
19Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, et al. (2011) Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 105: 796-806.
20Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, et al. (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13: 2795-2803.
21Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111.
22Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, et al. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 4: e7287.
23WeickhardtA, Tebbutt N,Mariadason J (2010) Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. Curr Cancer Drug 10: 824-833.
24Modjtahedi H, Essapen S (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20: 851-855.
25Dempke WC, Heinemann V (2010) Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer Res 30: 4673-4677.
26Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, et al. (2012) Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23: 2153-2161.
27Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, et al. (2012) A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 18: 3407-3413.
28Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, et al. (2011) A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17: 6304-6312.
29Bitelman C, Sarfstein R, Sarig M, Attias-Geva Z, Fishman A, et al. (2013) IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer. Cancer Lett 335: 153-159.
30Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ, et al. (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235-2249.
31Marches R, Uhr JW (2004) Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer 112: 492-501.
32Lin NU, Carey LA, Liu MC, Younger J, Come SE, et al. (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993-1999.
33Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
34Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
35Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, et al. (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 58: 1887-1896.
36Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, et al. (2009) Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 69: 2191-2194.
37Chen FL, Xia W, Spector NL (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14: 6730-6734.
38Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919.
39Nanda R (2007) Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials 2: 111-116.
40Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, et al. (2009) An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 8: 2152-2162.
41Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, et al. (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294: 211-219.
42Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, et al. (2011) Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochem Biophys Res Commun 407: 412-419.
43Barok M, Tanner M, Köninki K, Isola J (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Research 13: R46.
44Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, et al. (2010) Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol 37: 669-678.
45García-Sáenz JA, Martín M, Calles A, Bueno C, Rodríguez L, et al. (2008) Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 20: 632-639.
46Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 786-792.
47Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S (2011) The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 22: 1308-1317.
48Pegram MD, Lopez A, Konecny G, Slamon DJ (2000) Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27: 21-25 (discussion 92-100).
49Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28: 13-19.
50Boone JJ, Bhosle J, Tilby MJ, Hartley JA, Hochhauser D (2009) Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 8: 3015-3023.
51Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M (2001) Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 21: 1301-1305.
52Winer EP, Burstein HJ (2001) New combinations with Herceptin in metastatic breast cancer. Oncology 61: 50-57.
53Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, et al. (2006) Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12: 600-607.
54Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, et al. (2010) Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res 30: 473-480.
55Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, et al. (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909-916.
56Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, et al. (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17: 871-879.
57Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, et al. (2010) Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 9: 1286-1297.
58Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, et al. (2010) GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer10: 397.
59Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, et al. (2002) Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 62: 2034-2042.
60Kaneko T, Willner D, Monkovíc I, Knipe JO, Braslawsky GR, et al. (1991) New hydrazone derivatives of adriamycin and their immunoconjugates--a correlation between acid stability and cytotoxicity. Bioconjugate Chem 2: 133-141.
61Di Stefano G, Lanza M, Kratz F, Merina L, Fiume L (2004) A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur J Pharm Sci 23: 393-397.
62Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, et al. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 45: 5523-5533.
63Unger C, Häring B, Medinger M, Drevs J, Steinbild S, et al. (2007) Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin. Clin Cancer Res 13: 4858-4866.
64Mazuel C, Grove J, Gerin G, Keenan KP (2003) HPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasma. J Pharm Biomed Anal 33: 1093-1102.
65Greenfield RS, Kaneko T, Daues A, Edson MA, Fitzgerald KA, et al. (1990) Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res 50: 6600-6607.
66Coyne CP, Ross MK, Bailey JG (2009) Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. J Drug Targeting 17: 474-489.
67Lau A, Bérubé G, Ford CH, Gallant M (1995) Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro. Bioorganic and Medicinal Chemistry 3: 1305-1312.
68Kruger M, Beyer U, Schumacher P, Unger C, Zahn H, et al. (1997) Synthesis and Stability of Four Maleimide Derivatives of the Anticancer Drug Doxorubicin for the Preparation of Chemoimmunoconjugates. Chem Pharm Bull 45: 399-401.
69Furgeson DY, Dreher MR, Chilkoti A (2006) Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. J Control Release 110: 362-369.
70Liang JF, Yang VC (2005) Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett 15: 5071-5075.
71Sirova M, Strohalm J, Subr V, Plocova D, Rossmann P, et al. (2007) Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol Immunother 56: 35-47.
72Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, et al. (2001) PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 29: 313-318.
73Bidwell GL 3rd, Davis AN, Fokt I, Priebe W, Raucher D (2007) A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 25: 313-326.
74Abu Ajaj K, Graeser R, Fichtner I, Kratz F (2009) In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64: 413-418.
75Ryppa C, Mann-Steinberg H, Fichtner I, Weber H, Satchi-Fainaro R, et al. (2008) In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3. Bioconjugate Chem 19: 1414-1422.
76Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, et al, (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chem Bio Chem 10: 862-868.
77Ren Y, Wei D, Zhan X (2005) Inhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line (KB-A-1) by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro. Biotechnol Appl Biochem 41: 137-143.
78Ren Y, Zhan X, Wei D, Liu J (2004) In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate. Biomed Pharmacother 58: 520-526.
79Kovar L, Etrych T, Kabesova M, Subr V, Vetvicka D, et al. (2010) Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells. Tumour Biol 31: 233-242.
80Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, et al. (2009) Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30: 3466-3475.
81Krakovicova H, Ethch T, Ulbrich K (2009) HPMA-based polymer conjugates with drug combinations. Eur J Pharmacol 37: 4050-4412.
82Cao N, Feng SS (2008) Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 29: 3856-3865.
83Rodrigues PC, Beyer U, Schumacher P, Roth T, Fiebig HH, et al. (1999) Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. BioorgMed Chem 7: 2517-2524.
84Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171-183.
85Coyne CP, Jones T, Sygula A, Bailey J, Pinchuk L (2011) Epirubicin-[anti-HER2/neu] synthesized with an epirubicin-(C13-imino)-EMCS analog: Anti-neoplastic activity againstchemotherapeutic-resistant SKBr-3 mammary carcinoma in combination with organic selenium. Journal of Cancer Therapy 2: 22-39.
86Inoh K, Muramatsu H, Torii S, Ikematsu S, Oda M, et al. (2006) Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug. Jpn J Clin Oncol 36: 207-211.
87Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, et al. (2003) Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 9: 6567-6571.
88Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, et al. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 11: 5257-5264.
89Yang HM, Reisfeld RA (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci 85: 1189-1193.
90Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, et al. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261: 212-215.
91Diener E, Diner UE, Sinha A, Xie S, Vergidis R, et al. (1986) Specific immunosuppression by immunotoxins containing daunomycin. Science 231: 148-150.
92Dillman RO, Johnson DE, Ogden J, Beidler D (1989) Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Mol Biotherapy 1: 250-255.
93Page M, Thibeault D, Noel C, Dumas L (1990) Coupling a preactivated daunorubicin derivative to antibody. A new approach. Anticancer Research 10: 353-357.
94Reményi J, Balázs B, Tóth S, Falus A, Tóth G, et al. (2003) Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin. Biochem Biophys Res Commun 4,303: 556-561.
95Ogden JR, Leung K, Kunda SA, Telander MW, Avner BP, et al. (1989) Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity. Molecular Biotherapy 1: 170-174.
96Sivam GP, Martin PJ, Reisfeld RA, Mueller BM (1995) Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 55: 2352-2356.
97Coyne CP, Jones T, PharrT (2011) Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Bioorganic and Medicinal Chemistry 19: 67-76.
98Coyne CP, Jones T, Bear R (2012) Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. Journal of Cancer Therapy: Breast Cancer Special Issue 3: 689-711.
99Coyne CP, Jones T, Bear R (2013) Gemcitabine-(C4-amide)- [anti-HER2/neu] Anti- Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic- Resistant Mammary Adenocarcinoma. J Clin Exp Oncol 2: 2.
100Kirstein MN, Hassan I, Guire DE, Weller DR, Dagit JW, et al. (2006) High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. J Chromatogr B: Biomed Sci Appl 835: 136-142.
101Reichelova V, Albertioni F, Liliemark J (1996) Determination of 2-chloro-2'-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 682: 115-123.
102Coyne CP, Jones T, Bear R (2012) Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate. Cancer Biother Radiopharm 27: 41-55.
103Beyer U, Rothen-Rutishauser B, Unger C, Wunderli-Allenspach H, Kratz F (2001) Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharmacol Res 18: 29-38.
104Sinkule JA, Rosen ST, Radosevich JA (1991) Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. Tumour Biol 12: 198-206.
105Johnson DA, Briggs SL, Gutowski MC, Barton R (1995) Anti-tumor activity of CC49-doxorubicin immunoconjugates. Anticancer Res 15: 1387-1393.
106Stan AC, Radu DL, Casares S, Bona CA, Brumeanu TD (1999) Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res 59: 115-121.
107Herbert C, Norris K, Sauk JJ (2003) Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates. J Drug Target 11: 101-107.
108Zhang Y, Wang N, Li N, Liu T, Dong Z (1992) The antitumor effect of adriamycin conjugated with monoclonal antibody against gastric cancer in vitro and in vivo. Acta Pharmaceutica Sinica 27: 325-330.
109Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, et al. (1986) Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res 46: 4886-4891.
110Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, et al. (1997) Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 57: 4530-4536.
111Muldoon LL, Neuwelt EA (2003) BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol 65: 49-62.
112Muldoon LL (2003) Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats. Neurosurgery 53: 1406-1412.
113Remsen LG, Trail PA, Hellstrom I, Hellstrom KE, Neuwelt EA (2000) Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 46: 704-709.
114Guo P, Ma J, Li S, Guo Z, Adams AL, et al. (2001) Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol 48: 169-176.
115Lagisetty P, Vilekar P, Awasthi V (2009) Synthesis of radiolabeled cytarabine conjugates. Bioorganic Med Chem Lett 19: 4764-4767.
116Castelli F, Sarpietro MG, Ceruti M, Rocco F, Cattel L (2006) Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Mol Pharm 3: 737-744.
117Guo Z, Gallo JM (1999) Selective Protection of 2',2'-Difluorodeoxycytidine (Gemcitabine). J Org Chem 64: 8319-8322.
118Lau A, Berube G, Ford CH, Gallant M (1995) Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in-vivo. Bioorganic and Medicinal Chemistry 3: 1305-1312.
119Ali SM, Khan AR, Ahmad MU, Chen P, Sheikh S, et al. (2005) Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002). Bioorg Med Chem Lett 15: 2571-2574.
120Chen P, Chien PY, Khan AR, Sheikh S, Ali SM, et al. (2006) In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate. Anticancer Drugs 17: 53-61.
121Alexander RL, Greene BT, Torti SV, Kucera GL (2005) A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Cancer Chemother Pharmacol 56: 15-21.
122Kiew LV, Cheong SK, Sidik K, Chung LY (2010) Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation. Int J Pharm 391: 212-220.
123Alexander RL, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL (2003) Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside. J Med Chem 46: 4205-4208.
124Alexander RL, Kucera GL (2005) Lipid nucleoside conjugates for the treatment of cancer. Curr Pharm Des 11: 1079-1089.
125Shih LB, Goldenberg DM, Xuan H, Lu HW, Mattes MJ, et al. (1994) Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol Immunother 38: 92-98.
126Hansen HJ, Ong GL, Diril H (1996) Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 320: 293-300.
127Pimm MV, Paul MA, Ogumuyiwa Y, Baldwin RW (1988) Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts. Cancer Immunol Immunother 27: 267-271.
128Zhang J, Antonyak MA, Singh G, Cerione RA (2013) A novel mechanism for the up-regulation of EGF-receptor levels in glioblastomas. Cell Rep 3: 2008-2020.
129Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, et al. (2013) Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol 7: 379-391.
130Wang F, Jiang X, Yang DC, Elliott RL, Head JF (2000) Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res 20: 799-808.
131Régina A, Demeule M, Ché C, Lavallée I, Poirier J, et al. (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155: 185-197.
132Asakura T, Takahashi N, Takada K, Inoue T, Ohkawa K (1997) Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells. Anticancer Drugs 8: 199-203.
133Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, et al. (2001) Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 12: 107-116.
134Lam W, Leung CH, Chan HL, Fong WF (2000) Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran size. Anticancer Drugs 11: 377-384.
135Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA (2008) Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci 105: 12128-12133.
136Liu JH, Cao L, Luo PG, Yang ST, Lu F, et al. (2010) Fullerene-conjugated doxorubicin in cells. ACS Appl Mater Interfaces 2: 1384-1389.
137Widakowich C, Dinh P, de Azambuja E, Awada A,Piccart-Gebhart M (2008) HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anticancer Agents Med Chem 8: 488-496.
138Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30: 1426-1447.
139Cameron DA, Stein S (2008) Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5: 512-520.
140Slamon DJ, Clark GM, Wong SG (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
141Loew S, Schmidt U, Unterberg A, Halatsch ME (2009) The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9: 703-715.
142Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
143Shen H, Lee FY, Gan J (2011) Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 337: 423-432.
144Liu F, Liu S, He S, Xie Z, Zu X, et al. (2010) Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Oncol Rep 23: 1469-1475.
145Patwardhan G, Gupta V, Huang J, Gu X, Liu YY (2010) Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol 80: 72-79.
146Pasquier J, Magal P, Boulangé-Lecomte C, Webb G, Foll F (2011) Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol Direct 6: 5.
147Chekhun VF, Zhylchuk VE, Lukyanova NY, Vorontsova AL, Kudryavets YI (2009) Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients. Exp Oncol 31: 123-124.
148Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, et al. (2012) Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol 69: 1117-1126.
149El Serafi MM, El Khodary AI, El Zawahry HR, Mansour OM, Gaballa HE (2006) Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study. J Egypt Natl Canc Inst 18: 209-215.
150Haas NB, Lin X, Manola J, Pins M, Liu G, et al. (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 29: 761-767.
151Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, et al. (2013) Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 119: 1555-1561.
152Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44: 117-123.
153Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, et al. (2003) Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer 39: 1547-1551.
154Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, et al. (2006) In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 95: 289-297.
155Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 100: 2936-2943.
156Wong SJ, Myette MS, Wereley JP, Chitambar CR (1999) Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clin Cancer Res 5: 439-443.
157Zhou B, Mi S, Mo X, Shih J, Tsai J, et al. (2002) Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Res 22: 1369-1377.
158Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, et al. (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3: 279-290.
159Ricciardi S, Mey V, Nannizzi S, Pasqualetti G, Crea F, et al. (2010) Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy 56: 303-312.
160Coyne CP, Jones T, Bear R (2012) Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate. Cancer and Clinical Oncology 1: 49-80.
161Jin R, Moreira Teixeira LS, Krouwels A, Dijkstra PJ, van Blitterswijk CA, et al. (2010) Synthesis and characterization of hyaluronic acid-poly(ethylene glycol) hydrogels via Michael addition: An injectable biomaterial for cartilage repair. Acta Biomater 6: 1968-1977.
162Fry AK, Schilke KF, McGuire J, Bird KE (2010) Synthesis and anticoagulant activity of heparin immobilized "end-on" to polystyrene microspheres coated with end-group activated polyethylene oxide. J Biomed Mater Res B Appl Biomater 94: 187-195.
163Coyne CP, Fenwick BW, Ainsworth J (1997) Cytotoxic activity of doxorubicin "loaded" neutrophils against human mammary carcinoma (HTB-19). Biotherapy 10: 145-159.
164Shen WC, Ryser HJ (1981) cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys Res Commun 102: 1048-1054.
165Aboud-PirakE, Hurwitz E, Bellot F, Schlessinger J, Sela M (1989) Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor. Proc Natl Acad Sci 86: 3778-3781.
166Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, et al. (2008) Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 99: 760-767.
167Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, et al. (2003) Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 42: 97-102.
168Bierau J, van Gennip AH, Leen R, Meinsma R, Caron HN, et al. (2006) Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. Cancer Chemother Pharmacol 57: 105-113.
169Santini V, D'Ippolito G, Bernabei PA, Zoccolante A, Ermini A, et al. (1996) Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leuk Res 20: 37-45.
170Yang HM, Reisfeld RA. (1988) Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan. J Natl Cancer Inst 80: 1154-1159.
171Lutsenko SV, Feldman NB, Severin SE (2002) Cytotoxic and antitumor activities of doxorubicin conjugates with the epidermal growth factor and its receptor-binding fragment. J Drug Target 10: 567-571.
172Mueller H, Kassack MU, Wiese M (2004) Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. Biomolecular Screening 9: 506-515.
173Ulukaya E, Ozdikicioglu F, Oral AY, Dermirci M (2008) The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro 22: 232-239.
174Varache-Lembège M, Larrouture S, Montaudon D, Robert J, Nuhrich A (2008) Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes. Eur J Med Chem 43: 1336-1343.
175Kars MD, Iseri OD, Gunduz U, Molnar J (2008) Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 54: 194-200.
176Huang H, Pierstorff E, Osawa E, Ho D (2007) Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett 7: 3305-3314.
177Dery MC, Van Themsche C, Provencher D, Mes-Masson AM, Asselin E (2007) Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro. Reprod Biol Endocrinol 5: 38-39.
178Spee B, Jonkers MD, Arends B, Rutteman GR, Rothuizen J, et al. (2006) Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol Cancer 5: 34.
179Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, et al. (2010) Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm 7: 2255-2269.
180Martarelli D, Pompei P, Baldi C, Mazzoni G (2008) Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 61: 809-817.
181Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL (2005) Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55: 425-432.
182Morris DL, Jourdan JL, Pourgholami MH (2001) Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 61: 42-46.
183Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, et al. (2001) In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165: 43-49.
184Khalilzadeh A, Wangoo KT, Morris DL, Pourgholami MH (2007) Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 74: 407-414.
185Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, et al. (2010) The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115: 4824-4833.
186Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA(2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 8: 2963-2969.
187Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, et al. (2002) The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 1: 1201-1209.
188Doudican N, Rodriguez A, Osman I, Orlow SJ (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 6: 1308-1315.
189Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL (2011) Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935.
190Pourgholami MH, Cai ZY, Badar S, Wangoo K, Poruchynsky MS, et al. (2010) Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole. BMC Cancer 10:143.
191Pourgholami MH, Cai ZY, Wang L, Badar S, Links M, et al. (2009) Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. Cancer Invest 27: 171-177.
192Nianjun H, Cerepnalkoski L, Nwankwo JO, Dews M, Landolph JR (1994) Induction of chromosomal aberrations, cytotoxicity, and morphological transformation in mammalian cells by the antiparasitic drug flubendazole and the antineoplastic drug harringtonine. Fundam Appl Toxicol 22: 304-313.